This technology includes a device to allow chemists to process crude reaction mixtures with the objective of isolating the desired product from reaction by-products and other solvents and impurities to provide material of adequate quality and purity to be submitted for further chromatographic purification or used directly in subsequent reactions. The instrument serves in facilitating the integration of a close-to-universal set of isolation techniques collectively referred to as “solid-phase extraction” (SPE) methods.

This technology includes the use of the Anneal-Pool-Ligate-Sequence method (APLS) to quantify the cellular expression of dozens of genes for high throughput chemical library screening. This method is performed by culturing eucaryotic cells in 384-well format microplates, treating the cells with a library of chemicals, and producing cell lysates. Oligodeoxynucleotide (oligo) pairs representing (21) selected genes, and carrying index sequences for each well (384) and microplate (26), are annealed to mRNAs in cell lysates.

This technology includes methods for the biofabrication of full thickness skin tissues in 12, 24, 48 and 96-well plates, using commercially available hardware to enable the implementation of large-scale toxicity and efficacy testing of chemical and biologics.

This technology includes the enablement of the nanoliter-scale transfer of biological liquids in array format from a microplate (source plate) containing cultured cells or other protein-containing mixtures onto a nitrocellulose membrane that has been mounted within a custom-designed target plate. Using this method and the prototype nitrocellulose target plate, reverse phase protein arrays can be generated in which protein levels from each well transferred onto the membrane can be detected and quantified.

This technology includes device and sensor selection for the detection of blood metabolites which can be used to diagnose and monitor diseases in real-time. Currently the monitoring of metabolite levels is performed with specialized mass spectrometry instrumentation, therefore patient quality-of-life and financial advantages exist to develop devices capable of detecting metabolites in real-time.

This technology includes the development of devices capable of real-time evaluation of metabolite levels for the treatment of numerous metabolic disorders, including hyperammonemia and aminoacidopathies. Currently, the monitoring of metabolite levels is done in a hospital setting with specialized mass spectrometry instrumentation. As a consequence, susceptible patients who are undergoing a crisis need to visit the hospital for testing to determine if there is a metabolite disturbance.

This technology includes Cyclopentane-modified Peptide Nucleic Acids (cp-PNAs) which can be combined with (forced-intercalation) FIT-PNAs to create highly sensitive probes that detect the presence of complementary RNA sequences. We have studied the beneficial effects of incorporating cyclopentane groups into the backbone of PNAs, which leads to proper preorganization of the PNA backbone into the conformations needed to bind complementary RNA sequences. The cp-PNAs typically have improved thermodynamic stability for binding to complementary nucleic acids compared to unmodified PNAs.

This technology includes a semi-automatic and affordable protein purification system that produces purified proteins with yields and purities comparable to an automatic protein purification system for less than 10% of its cost, which can be used for studying protein structure and function, as well as antibody purifications and drug screenings. Additionally, the new system is flexible and customizable for use with both custom-made and commercial pre-made resin columns with either gravity flow or low-pressure configurations.

This technology includes a group of radioligands that label inflammatory cells specifically, accurately, and across different genotypes and can be detected using Positron Emission Tomography (PET). The radioligands target the Translocator protein 18 kDa (TSPO) receptor which is present on the outer mitochondrial membrane and is involved in the production of steroids. Current TSPO radioligands either lack specificity or have highly variable inter-subject sensitivities due to TSPO genotypic differences.

This technology includes a product for local delivery of alkaline phosphatase for the treatment of periodontal disease. Our laboratory has discovered that factors regulating phosphate metabolism and specifically the appropriate balance between phosphate (Pi) and pyrophosphate (PPi) at local sites are needed for formation (development), maintenance and regeneration of the tooth root surface (cementum), periodontal ligament (PDL) and surrounding alveolar bone, i.e., the periodontal apparatus.